Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 17, 2023 9:04am

124 Views

Post# 35501620

RE:RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.

With Merck's acquisition of the Phase 2 company Prometheus Biosciences for US$10.8 Billion, an acquisition of ONCY for between US$10 and US$15 Billion represents "good value" to any Big Pharma acquirer, given what we know about the safety and effectiveness of ONCY's platform technology pelareorep in the treatment of multiple cancers.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec